Technical Report No. 60-3
Process Validation: A Lifecycle Approach
Annex 2: Biopharmaceutical Drug Substances Manufacturing
Rebecca A. Devine, PhD, Independent Regulatory Consultant, Co-leader
Udesh de Silva, PhD, Samsung Biologics, Co-leader
Ronald Bates, PhD, Bristol-Meyers-Squibb
Igoris Čajevskis, Merck & Co., Inc.
Vijay Chiruvolu, PhD, Instil Bio
Lara Collier, Genentech, a member of the Roche Group
Michael R. De Felippis, PhD, Eli Lilly and Company, Inc.
Monica Lent, Genentech, a member of the Roche Group
John McShane, Validant
Morten Munk, Fujifilm Diosynth Biotechnologies
Randi Saunders, PhD, Merck & Co., Inc.
Ken Wong, Sanofi-Pasteur
Zhaoli Zhou, PhD, Independent Consultant
Wendy Zwolenski-Lambert, Novartis AG
Process Validation: A Lifecycle Approach

Annex 2: Biopharmaceutical Drug Substances Manufacturing

Technical Report No. 60-3

ISBN: 978-1-945584-24-4
© 2021 Parenteral Drug Association, Inc.
All rights reserved.
Table of Contents

1.0 INTRODUCTION ..............................................1
   1.1 Purpose and Scope ..................................1

2.0 GLOSSARY OF TERMS ......................................2
   2.1 Abbreviations .......................................6

3.0 STAGE 1: BUILDING AND CAPTURING PROCESS KNOWLEDGE — PROCESS DESIGN .................6
   3.1 Sequence of Activities Leading Up to Stage 2 — Process Performance Qualification ........7
   3.2 Analytical Methods ..................................7
   3.3 Risk Assessments ....................................9
   3.4 Platform Technology Application during Development ...............................................10
   3.5 Quality Target Product Profile and Critical Quality Attribute Assignment ......................10
   3.6 Control Strategy ......................................12
      3.6.1 Risk Assessment to Support Control Strategy Development ....................................13
      3.6.2 Critical Process Parameters ......................13
      3.6.3 Noncritical Process Parameters .................13
      3.6.4 Process Characterization .......................14
      3.6.5 Criticality Assessment of Raw Materials ....16

4.0 STAGE 2: PROCESS QUALIFICATION ......................17
   4.1 Readiness .............................................18
      4.1.1 Equipment and Facilities .......................18
      4.1.2 Methods .........................................19
      4.1.3 Raw Materials ...................................19
   4.2 Process Validation ....................................20
      4.2.1 Process Performance Qualification ..........20
      4.2.2 Process Validation Studies ....................23
      4.2.3 Validation of Single-Use Systems ............32

5.0 STAGE 3: LIFECYCLE MANAGEMENT .....................33
   5.1 Ongoing Process Verification Approaches ..........33
   5.2 Transfer of Biopharmaceutical Manufacturing Processes .............................................34
      5.2.1 Process Transfer and Adaptation ...............34
      5.2.2 Product Comparability and Stability ............35
      5.2.3 Multisite Manufacturing of Biopharmaceutical Products ........................................35

6.0 REFERENCES .................................................35

7.0 APPENDIX 1: EXAMPLE OF FAILURE MODES AND EFFECTS ANALYSIS .......................39

8.0 APPENDIX 2: EXAMPLE OF SCALE-DOWN MODEL QUALIFICATION ..........................40

9.0 APPENDIX 3: UNIT OPERATIONS USED IN BIOPHARMA PROCESSES ......................41
   9.1 Expression Construct and Cell-Line Development and Characterization .........................41
   9.2 Vial Thaw and Cell Expansion (Seed Train) ...........41
   9.3 Production Bioreactor (Fermentation/Cell Culture) ......................................................41
   9.4 Cell Culture ..........................................42
   9.5 Harvest ..............................................43
   9.6 Capture Chromatography ................................43
   9.7 Viral Inactivation ....................................43
   9.8 Polishing Chromatography ............................43
   9.9 Ultrafiltration and Diafiltration ......................45
   9.10 Drug Substance Filling ................................45
   9.11 Single-use Bioreactor Cell Culture .................45
   9.12 Reactions ...........................................45
   9.13 Conjugation (e.g., Drug, Vaccine) .................45

FIGURES AND TABLES INDEX

Table 3.2-1  Examples of In-Process Test and Lot Release Assays ..................................8
Figure 4.0-1  Activities Leading Up to Process Validation .............................................18
Table 7.0-1  Example FMEA: Failure Modes and Effects Analysis ..................................39
Table 8.0-1  Scale-Down Variables ............................................................40
Table 8.0-2  Chromatography Column Scale-Down Verification Example ......................40
Table 9.2-1  Example: Process Parameters and Performance Indicators .........................42
Table 9.3-1  Example: Process Parameters and Performance Indicators .........................42
Table 9.4-1  Example: Process Parameters and Performance Indicators .........................42
Table 9.5-1  Example: Process Parameters and Performance Indicators .........................43
Table 9.6-1  Example: Process Parameters and Performance Indicators .........................44
Table 9.7-1  Example: Process Parameters and Performance Indicators .........................44
Table 9.8-1  Example: Process Parameters and Performance Indicators .........................44
Table 9.9-1  Example: Process Parameters and Performance Indicators .........................45
Table 9.10-1 Example: Process Parameters and Performance Indicators .......................45
Table 9.12-1 Example: Process Parameters and Performance Indicators .......................46
Table 9.13-1 Example: Process Parameters and Performance Indicators .......................46